2-((8-methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy)acetohydrazide | 1246440-45-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 新黄酮类化合物
• 英文名称: 2-((8-methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy)acetohydrazide
• CAS: 1246440-45-8
• 化学式: C₁₈H₁₆N₂O₄
• 分子量: 324.336
• InChiKey: KUZQZQMNIJMKCK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.14
• 重原子数：
  24.0
• 可旋转键数：
  4.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  94.56
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  二硫化碳 、 2-((8-methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy)acetohydrazide 在 potassium hydroxide 、 盐酸 、 水 作用下， 以 乙醇 为溶剂， 反应 48.0h， 以98%的产率得到7-[(5-mercapto-1,3,4-oxadiazol-2-yl)methoxy]-8-methyl-4-phenyl-2H-1-benzopyran-2-one
  参考文献：
  名称：

  Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity

  摘要：

  Novel series of 7-substituted-benzopyran-2-ones was synthesized by incorporating heterocyclic rings as oxadiazole, triazole, pyrazole or pyrazolin-5-one to benzopyran-2-one nucleus at p-7 via methylene-oxy or acetoxy linker. In-vitro anticancer activity was evaluated for these hybrids; twelve compounds were selected by National Cancer Institute for anticancer screening. Among them, compound 9a exhibited broad spectrum antitumor activity showing full panel median growth inhibition (GI(50)) = 5.46 mu M. According to docking results using Molsoft ICM 3.4-8c program, the target compounds may act through inhibition of topoismerase 1, where camptothecin is used as ligand. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.05.050
• 作为产物：
  描述：

  ethyl [(8-methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy]acetate 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 2-((8-methyl-2-oxo-4-phenyl-2H-chromen-7-yl)oxy)acetohydrazide
  参考文献：
  名称：

  Synthesis and docking studies of novel benzopyran-2-ones with anticancer activity

  摘要：

  Novel series of 7-substituted-benzopyran-2-ones was synthesized by incorporating heterocyclic rings as oxadiazole, triazole, pyrazole or pyrazolin-5-one to benzopyran-2-one nucleus at p-7 via methylene-oxy or acetoxy linker. In-vitro anticancer activity was evaluated for these hybrids; twelve compounds were selected by National Cancer Institute for anticancer screening. Among them, compound 9a exhibited broad spectrum antitumor activity showing full panel median growth inhibition (GI(50)) = 5.46 mu M. According to docking results using Molsoft ICM 3.4-8c program, the target compounds may act through inhibition of topoismerase 1, where camptothecin is used as ligand. (C) 2010 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2010.05.050